New softgels ship seven occasions extra CBDA and CBD than authentic uncooked components to assist a wholesome inflammatory response and to handle occasional soreness
CV Sciences Provides +PlusCBD Aid Softgels to Wellness Line of CBD Merchandise
SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Firm”, “CV Sciences”, “our”, “us” or “we”), a preeminent provider and producer of hemp cannabidiol (CBD) merchandise, as we speak introduced the addition of +PlusCBD Aid Softgels to its Wellness line of CBD merchandise, becoming a member of our extremely profitable +PlusCBD Sleep & Calm Gummies.
+PlusCBD Aid Softgels ship seven occasions extra CBDA and CBD than the unique +PlusCBD Uncooked components and have Levagen®+ PEA, the CBD-like compound proven by scientific research to be an alternative choice to ibuprofen. This extremely optimized trio promotes a wholesome inflammatory response and gives a secure various in serving to to handle occasional soreness.
“We imagine that +PlusCBD Aid Softgels include the most secure, purest and only supply of CBD/CBDA accessible available on the market as we speak,” mentioned Joseph Dowling, Chief Govt Officer of CV Sciences. “Our work at CV Sciences facilities across the potential for CBD to rework our understanding of well being, wellness and ache reduction. The +PlusCBD Aid Softgels symbolize one other step in our mission to supply revolutionary and secure alternate options to enhance well being, leveraging CBD/CBDA and PEA. Our product growth staff creates best-in-class, revolutionary merchandise that go well with particular person preferences, deal with want states and assist customers profit from CBD in the way in which that works finest for them. Our Aid product is now accessible straight from our web site www.pluscbdoil.com and shortly from choose retailers.”
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct enterprise segments: a shopper product division centered on manufacturing, advertising and promoting plant-based dietary dietary supplements and CBD merchandise to a spread of market sectors; and a drug growth division centered on growing and commercializing CBD-based novel therapeutics. The Firm’s +PlusCBD™ merchandise are bought at greater than 8,400 retail places all through the U.S. and it is without doubt one of the top-selling manufacturers of hemp-derived CBD within the pure merchandise market, based on SPINS, the main supplier of syndicated knowledge and insights for the pure, natural and specialty merchandise trade. CV Sciences follows all pointers for Good Manufacturing Practices (GMP) and the Firm’s merchandise are processed, produced, and examined all through the manufacturing course of to substantiate strict compliance with firm requirements and specs. With a dedication to science, +PlusCBD™ product advantages in wholesome persons are supported by human scientific analysis knowledge, along with three printed scientific case research accessible on PubMed.gov. +PlusCBD™ was the primary hemp CBD complement model to put money into the scientific proof essential to obtain self-affirmed Typically Acknowledged as Protected (GRAS) standing. CV Sciences, Inc. has main places of work and amenities in San Diego, California. Further info is obtainable from OTCMarkets.com or by visiting www.cvsciences.com.
Ahead Trying Statements
This press launch could include sure forward-looking statements and data, as outlined inside the which means of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934, and is topic to the Protected Harbor created by these sections. This materials incorporates statements about anticipated future occasions and/or monetary outcomes which can be forward-looking in nature and topic to dangers and uncertainties. Such forward-looking statements by definition contain danger and uncertainties.
Contact Data
Investor Contact:
ICR
Reed Anderson
646-277-1260
[email protected]
Media Contact:
ICR
Cory Ziskind
646-277-1232
[email protected]
A photograph accompanying this announcement is obtainable at https://www.globenewswire.com/NewsRoom/AttachmentNg/57df619a-f57d-409c-8385-25478808872f
